Related Experiment Video
Updated: May 21, 2026
Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
Nucleic acids in human glioma treatment: innovative approaches and recent results
S Catuogno1, C L Esposito, C Quintavalle
1Istituto per l'Endocrinologia e l'Oncologia Sperimentale del CNR "G. Salvatore", Via Pansini 5, 80131 Naples, Italy.
Abstract:
Gliomas are the most common primary central nervous system tumors with a dismal prognosis. Despite recent advances in surgery, radiotherapy, and chemotherapy, current treatment regimens have a modest survival benefit. A crucial challenge is to deliver drugs effectively to invasive glioma cells residing in a sanctuary within the central nervous system. New therapies are essential, and oligonucleotide-based approaches, including antisense, microRNAs, small interfering RNAs, and nucleic acid aptamers, may provide a viable strategy. Thanks to their unique characteristics (low size, good affinity for the target, no immunogenicity, chemical structures that can be easily modified to improve their in vivo applications), these molecules may represent a valid alternative to antibodies particularly to overcome challenges presented by the blood-brain barrier. Here we will discuss recent results on the use of oligonucleotides that will hopefully provide new effective treatment for gliomas.
Insights
Oligonucleotide-based therapies offer a promising new strategy for treating gliomas, a type of brain tumor. These molecules can effectively target invasive glioma cells, potentially overcoming challenges associated with the blood-brain barrier.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Drug Delivery
Background:
- Gliomas are primary central nervous system tumors with poor prognoses.
- Current treatments like surgery, radiotherapy, and chemotherapy offer limited survival benefits.
- Efficient drug delivery to invasive glioma cells within the central nervous system remains a significant challenge.
Purpose of the Study:
- To explore the potential of oligonucleotide-based therapies for treating gliomas.
- To discuss the advantages of oligonucleotides in overcoming the blood-brain barrier for brain tumor treatment.
Main Methods:
- Review of recent research on oligonucleotide applications in glioma treatment.
- Discussion of oligonucleotide characteristics relevant to in vivo applications and drug delivery.
Main Results:
- Oligonucleotides (including antisense, microRNAs, small interfering RNAs, and nucleic acid aptamers) show promise as a viable therapeutic strategy.
- Their small size, high affinity, low immunogenicity, and modifiable structures facilitate improved in vivo applications.
- Oligonucleotides may offer an alternative to antibodies for overcoming the blood-brain barrier.
Conclusions:
- Oligonucleotide-based approaches represent a potential breakthrough in developing new and effective treatments for gliomas.
- Further research and development in this area are crucial for improving patient outcomes in neuro-oncology.
